A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix75/25 in Subjects With Type 2 DM Who Are Treated With ≥ 150 Units of Insulin Per Day

Trial Profile

A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix75/25 in Subjects With Type 2 DM Who Are Treated With ≥ 150 Units of Insulin Per Day

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Insulin (Primary) ; Insulin neutral protamine lispro/insulin lispro
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Biodel
  • Most Recent Events

    • 12 Feb 2016 Last checked against ClinicalTrials.gov record.
    • 14 Sep 2015 According to a Biodel media release, results from this study will be presented at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD).
    • 09 Jun 2015 Results (pre- and post-prandial blood glucose concentrations) presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top